Product image of Micofenolato De Mofetil Generis (Mycophenolate Mofetil) supplied by GNH India

Micofenolato De Mofetil Generis

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Micofenolato De Mofetil Generis (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetil Generis, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent acute organ transplant rejection, treat lupus nephritis, and manage selected autoimmune diseases in adult and pediatric patients as appropriate.

GNH India supplies Micofenolato De Mofetil Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Manufacturer / TM Owner

Generis Phar, Unipessoal Lda.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mycophenolate Mofetil is used to modulate immune activity in transplant and autoimmune disease contexts.

  • Prevention of acute organ transplant rejection: reduces the risk of graft loss by suppressing lymphocyte proliferation.
  • Treatment of lupus nephritis: controls renal inflammation associated with systemic lupus erythematosus.
  • Management of certain autoimmune diseases: mitigates disease activity in conditions such as vasculitis or dermatomyositis.
  • Prevention of graft‑versus‑host disease in bone marrow transplantation: limits donor T‑cell activation and tissue damage.

How It Works

  • Mycophenolate Mofetil is converted intracellularly to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This blocks de novo synthesis of guanosine nucleotides, a pathway essential for the proliferation of T‑ and B‑lymphocytes, thereby dampening the adaptive immune response.

Side Effects

Adverse reactions may occur with Mycophenolate Mofetil therapy.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhea: frequent loose stools.
  • Vomiting: occasional emesis.
  • Abdominal pain: cramping or discomfort.
  • Headache: transient tension‑type headaches.
  • Upper respiratory infections: increased susceptibility to colds.

Serious or Rare Side Effects

  • Leukopenia or neutropenia: significant drop in white blood cells.
  • Anemia: reduced red blood cell count.
  • Severe infections: opportunistic or systemic infections.
  • Hepatic dysfunction: elevated liver enzymes or hepatitis.
  • Malignancy risk: potential increased risk of certain cancers.
  • Progressive multifocal leukoencephalopathy: rare viral brain infection.

Precautions & Warnings

Patients receiving Mycophenolate Mofetil should be monitored closely for safety.

  • Monitor blood counts: perform regular CBC to detect leukopenia or anemia.
  • Assess renal function: adjust dosing in patients with impaired kidney function.
  • Assess hepatic function: monitor liver enzymes periodically.
  • Avoid use in uncontrolled infection: risk of worsening infectious disease.
  • Pregnancy and lactation: discuss potential risks with the prescriber before use.
  • Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Avoid Interactions

Mycophenolate Mofetil can interact with several medicines.

Major Interactions (Avoid)

  • Azathioprine: additive bone‑marrow suppression may lead to severe cytopenias.
  • Live vaccines: increased risk of vaccine‑derived infection.

Moderate Interactions (Monitor Closely)

  • Antacids containing magnesium or aluminum: may reduce mycophenolate absorption; separate dosing by at least 2 hours.
  • Cyclosporine or tacrolimus: can increase mycophenolate exposure; monitor drug levels.
  • Warfarin: may potentiate anticoagulant effect; check INR more frequently.

Frequently Asked Questions

Micofenolato De Mofetil Generis, containing Mycophenolate Mofetil, is prescribed to prevent acute organ transplant rejection, to treat lupus nephritis, and to manage certain autoimmune diseases such as vasculitis or dermatomyositis by suppressing the immune response.

Mycophenolate Mofetil is metabolised to mycophenolic acid, which selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH). This blocks the de novo synthesis of guanosine nucleotides, a pathway required for the proliferation of T‑ and B‑lymphocytes, thereby reducing immune activity.

The appropriate dose of Micofenolato De Mofetil Generis is determined by the prescribing clinician based on the patient’s condition, weight, renal function and other individual factors. Patients should follow the exact regimen provided by their healthcare professional.

Safety in pregnancy and lactation has not been fully established. The prescriber should evaluate the potential benefits and risks before initiating therapy in pregnant or nursing patients, and discuss alternative options if appropriate.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mycophenolate Mofetil differs from calcineurin inhibitors such as cyclosporine by targeting nucleotide synthesis rather than calcium‑dependent signaling. This results in a distinct side‑effect profile and may be preferred when calcineurin‑related nephrotoxicity is a concern, though individual therapy should be guided by the clinician.

The product should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Micofenolato De Mofetil Generis is taken orally, usually with food or a glass of water to improve tolerability. The exact dosing schedule and whether the dose is divided throughout the day are determined by the prescribing clinician.

Serious risks include severe infections, leukopenia or neutropenia, hepatic dysfunction, and rare but potentially fatal conditions such as progressive multifocal leukoencephalopathy. Patients should be monitored regularly for blood counts and liver function, and any signs of infection should be reported promptly.

Patients with known hypersensitivity to Mycophenolate Mofetil or any component of the formulation should avoid the product. It is also contraindicated in individuals with uncontrolled active infections, and caution is advised in those with severe renal or hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT